Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates
Sensei Biotherapeutics (FTH) reported third-quarter GAAP earnings per share of -$0.79, missing analyst expectations by $0.01. Despite the slight earnings miss, the company demonstrated a significant increase in its liquidity position. As of September 30, 2026, Sensei Biotherapeutics held $174.8 million in cash, cash equivalents, and marketable securities, a substantial rise from the $21.2 million reported as of December 31, 2025. The company continues to focus on its lead assets, including Faeth Therapeutics' PI3K pathway inhibitor developments.
Tickers: $SENS
Topics: cash position earnings miss financial results
Read the full article at Seeking Alpha
Part of the story Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates (8 articles)